The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds

Toxicology and Applied Pharmacology

Volumn 263, Issue 2, 2012, Pages 171-183

  Marks, Louise ^a   Borland, Samantha ^a,b   Philp, Karen ^a   Ewart, Lorna ^a   Lainée, Pierre ^a,c   Skinner, Matthew ^a   Kirk, Sarah ^a   Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c SANOFI   (France)

Author keywords

Anaesthetised guinea pig; Cardiovascular attrition; DP dt max; ECG; Left ventricular contractility; QA interval

Indexed keywords

AMOXICILLIN; ATENOLOL; CLONIDINE; DOBUTAMINE; DOFETILIDE; FLECAINIDE; ISOPRENALINE; LEVOSIMENDAN; MILRINONE; MOXIFLOXACIN; NIFEDIPINE; PARACETAMOL; PENTOBARBITAL; VERAPAMIL;

ANESTHESIA; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; GUINEA PIG; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART MUSCLE CONTRACTILITY; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN;

ANESTHESIA; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; GUINEA PIGS; HEART RATE; INFUSIONS, INTRAVENOUS; MALE; MODELS, ANIMAL; MYOCARDIAL CONTRACTION; PHARMACEUTICAL PREPARATIONS; PHENOBARBITAL; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; CAVIA;

EID: 84865102276     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.06.007     Document Type: Article

References (69)

1. Alousi A.A., Iwan T., Edelson J., Biddlecombe C. Correlation of the hemodynamic and pharmacokinetic profile of intravenous milrinone in the anaesthetised dog. Arch. Int. Pharmacodyn. 1984, 267:59-66.
2. Anon S7A: Safety Pharmacological Studies for Human Pharmaceuticals. CPMP/ICH/539/00 Last accessed on 06/06/12. http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
3. Anon S7B: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization CHMP/ICH/423/02, Last accessed on 06/06/12. http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
4. Ashwell S., Janetka J.W., Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin. Investig. Drugs 2008, 17(9):1331-1340.
5. Berrebi-Bertrand I., Maixent J.M., Guede F.G., Gerbi A., Charlemagne D., Lelievre L.G. Two functional NaqrKq-ATPase isoforms in the left ventricle of the guinea pig heart. Eur. J. Biochem. 1991, 196:129-133.
6. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
7. Bombardini T. Myocardial contractility in the echo lab: molecular, cellular and pathophysiological basis. Cardiovasc. Ultrasound 2005, 3:27.
8. Cambridge D., Whiting M.V. Evaluation of the QA interval as an index of cardiac contractility in anaesthetized dogs: responses to changes in cardiac loading and heart rate. Cardiovasc. Res. 1986, 20(6):444-450.
9. Clifton G.D., Booth D.C., Hobbs S., Boucher B.A., Foster T.S., McAllister R.G., DeMaria A.N. Negative inotropic effect of intravenous nifedipine in coronary artery disease: relation to plasma levels. Am. Heart J. 1989, 119(2):283-290.
10. De Clerck F.D., Van de Water A., D'Aubioul J., Rong Lu H., van Rossem K., Hermans A., Van Ammel K. In vivo measurement of QT prolongation, dispersion and arrythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fund. Clin. Pharmacol. 2002, 16:125-140.
11. Deveney A.M., Kjellstrom A., Forsberg T., Jackson D.M. A pharmacological validation of radiotelemetry in conscious, freely moving rats. J. Pharmacol. Toxicol. Methods 1998, 40:71-79.
12. Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target. Oncol. 2011, 6(4):189-195.
13. Force T., Kerkelä R. Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem. Drug Discov. Today 2008, 13:778-784.
14. Gould S., Westwood F.R., Curwen J.O., Ashton S.E., Roberts D.W., Lovick S.C., Ryan A.J. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J. Natl Cancer Inst. 2007, 99:1724-1728.
15. Guiol C., Ledoussal C., Surgé J.M. A radiotelemetry system for chronic measurement of blood pressure and heart rate in the unrestrained rat validation of the method. J. Pharmacol. Toxicol. Meth. 1992, 28:99-105.
16. Guo L., Dong Z., Guthrie H. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J. Pharmacol. Toxicol. Meth. 2009, 60(2):130-151.
17. Guth B.D., Germeyer S., Kolb W., Markert M. Developing a strategy for the nonclinical assessment of proarrythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J. Pharmacol. Toxicol. Meth. 2004, 49:159-169.
18. Hahn T., Mogensen T., Lund C., Jacobsen L., Hjortsoe N., Rasmussen S., Rasmussen M. Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. Acta Anaesthesiol. Scand. 2003, 47:138-145.
19. Hamlin R.L., Del Rio C. An approach to the assessment of drug-induced changes in non-electrophysiological properties of cardiovascular function. J. Pharmacol. Toxicol. Methods 2010, 62(1):20-29.
20. Hamlin R.L., Kijtawornat A., Keene B.W., Hamlin D.M. QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol. Sci. 2003, 76(2):437-442.
21. Hammond T.G., Carlsson L., Davis A.S., Lynch W.G., Mackenzie I., Redfern W.S., Sullivan A.T., Camm A.J. Methods of collecting and evaluating non-clinical cardiac electrophysiological data in the pharmaceutical industry: results of an international survey. Cardiovasc. Res. 2001, 49:741-750.
22. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., Thomas K. ILSI_HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods 2006, 54:116-129.
23. + channel and drug-induced prolongation of the QRS complex. BJP. 2011, 164:260-273.
24. Harmer A.R., Abi-Gerges N., Morton M.J., Pullen G.F., Valentin J.P., Pollard C.E. Validation of an in vitro contractility assay using canine ventricular myocytes. TAAP 2012, 260(2):162-172.
25. Hauser D.S., Stade M., Schmidt A., Hanauer G. Cardiovascular parameters in anaesthetized guinea-pigs: a safety pharmacology screening model. J. Pharmacol. Toxicol. Methods 2005, 52(1):106-114.
26. Heath B.M., Cui Y., Worton S., Lawton B., Ward G., Ballini E., Doe C.P.A., Ellis C., Patel B.A., McMahon N.C. Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction showing from nonclinical models to clinical. J. Pharmacol. Toxicol. Methods 2011, 63:258-268.
27. ICHE14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrythmic Potential for Non-antiarrythmic Drugs CHMP/ICH/2/04, Last accessed on 06/06/12. http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
28. Jones A.L., Barlow M., Barrett-Lee P.J., Canney P.A., Gilmour I.M., Robb S.D., Plummer C.J., Wardley A.M., Verrill M.W. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br. J. Cancer 2009, 100(5):684-692.
29. Kägström J., Sjögren E.L., Ericson A.C. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. J. Pharmacol. Toxicol. Methods 2007, 56(2):186-193.
30. Kaheinen P., Pollesello P., Levijoki J., Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J. Cardiovasc. Pharmacol. 2004, 43:555-561.
31. Kaitin K.I., Di Masi J.A. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 2011, 89:183-188.
32. Kenward M.G., Roger J.H. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997, 53:983-997.
33. Knowlen G.G., Olivier B.N., Kittleson M.D. Cardiac contractility: a review 1973, 1(4):188-198.
34. Kowey P.R., Malik M. The QT interval as it relates to the safety of non-cardiac drugs. Eur. Heart J. 2007, (Suppl. 9, Suppl. G):G3-G8.
35. Lainée P. Incidence of cardiac contractility issues in safety pharmacological studies: is the core battery sufficient?. J. Pharmacol. Toxicol. Methods 2009, 60:252. (Abstract).
36. Laverty H.G., Benson C., Cartwright E.J., Cross M.J., Garland C., Hammond T.G., Holloway C., McMahon N., Milligan J., Park K., Pirmohamed M., Pollard C., Radford J., Roome N., Sager P., Singh S., Suter T., Suter W., Trafford A., Volders P.G.A., Wallis R., Weaver R., York M., Valentin J.P. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. 2011, 163(4):675-693.
37. Lecarpentier Y., Waldestrom A., Clergue M., Chemla D., Oliviero P., Martin J.L., Swynghedauw B. Major alterations in relaxation during cardiac hypertrophy induced by aortic stenosis in guinea pig. Circ. Res. 1987, 61:107-116.
38. Librizzi L., Biella G., Cimino C., Di Curtis M. Arterial supply of limbic structures in the guinea-pig. J. Comp. Neurobiol. 1999, 411:674-682.
39. Litwin D.C., Lengel D.J., Kamendi H.W., Bialecki R.A. An integrative pharmacological approach to radio telemetry and blood sampling in pharmaceutical drug discovery and safety assessment. BioMedical Engineering OnLine. 2011, 10:5.
40. LoRusso P.M., Gadgeel S.M., Wozniak A., Barge A.J., Jones H.K., DelProposto Z.S., DeLuca P.A., Evelhoch J.L., Boerner S.A., Wheeler C. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest. New Drugs 2008, 26:159-167.
41. Majewska-Michalska E. The vertebrobasilar arterial system in the guinea pig as compared with dog and human. Folia Morphol. (Warsz). 1998, 57:121-131.
42. McGough M.F., Pagel P.S., Lowe D., Hettrick D.A., Kersten J.R., Warltier D.C. Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs. J. Cardiothorac. Vasc. Anesth. 1997, 11(1):49-53.
43. Milrinone (Primacor®) prescribing information Last accessed on 06/06/12. http://www.globalrph.com/milrinone_dilution.htm.
44. Misu Y., Kubo T. Central and peripheral cardiovascular responses of rats to guanabenz and clonidine. The Japanese Journal of Pharmacology 1982, 32(5):925-928.
45. Mooney L., Marks L., Philp K.L., Skinner M., Coker S.J., Currie S. Optimising conditions for studying the acute effects of drugs on indices of cardiac contractility and on haemodynamics in anaesthetized guinea pigs. J. Pharmacol. Toxicol. Methods. 2012, 66(1):43-51.
46. Munos B. Lessons from 60years of pharmaceutical innovation. Nat. Rev. Drug Discov. 2009, 8:959-968.
47. National Archives, UK Animals (Scientific Procedures) Act Last accessed on 16/06/12. http://tna.europarchive.org/20100413151426/http://www.archive.official-documents.co.uk/document/hoc/321/321-xa.htm.
48. Ngo J. Correlation between dP/dtmax and QA interval, two cardiac contractility parameters, in the anaesthetized rat. J. Pharmacol. Toxicol. Methods 2009, 60(2):211.
49. Patmore L., Fraser S., Mair D., Templeton A. Effects of sparfloxin, grepfloxacin, moxifloxacin and ciprofloxacin on cardiac action potential duration. Eur. J. Pharmacol. 2000, 406:449-452.
50. Pettit S.D., Berridge B., Sarazan R.D. A call for more integrated cardiovascular safety assessment. J. Pharmacol. Toxicol. Methods 2010, 61(1):1-2.
51. Petty M.A., Reid J.L. The effect of opiates on arterial baroreceptor reflex function in the rabbit. Naunyn Schmiedeberg's Arch. Pharmacol. 1982, 319(3):206-211.
52. Pollard C.E., Gerges N.A., Bridgland-Taylor M.H., Easter A., Hammond T.G., Valentin J.-P. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. BJP 2010, 159:12-21.
53. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K.S., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
54. Redfern W.S., Ewart L., Hammond T.G., Bialecki R., Kinter L., Lindgren S., Pollard C.E., Roberts R., Rolf M.G., Valentin J.P. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. Toxicologist 2010, 114(S1):1081.
55. Sarazan R.D., Mittelstadt S., Guth B., Koerner J., Zhang J., Pettit S. Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities. Int. J. Toxicol. 2011, 30(3):272-286.
56. TM HT: a new high throughput electrophysiological measurement platform. J. Biomol. Screen. 2003, 8:50-64.
57. Segreti J.A., Marsh K.C., Polakowski J.S., Fryer R.M. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J. Pharmacol. Exp. Ther. 2008, 325:331-340.
58. Shamraj O.I., Grupp I.L., Melvin D., Gradoux N., Kremers W., Lingrel J.B., De Povel A. Characterisation of NarK-ATPase, its isoforms, and the inotropic response to ouabain in isolated failing human hearts. Cardiovasc. Res. 1993, 27:2229-2237.
59. Smith C., Sykes A., Robinson S., Thomas E. Evaluation of blood microsampling techniques and sampling sites for the analysis of drugs by HPLC-MS. Bioanalysis 2011, 3(5):145-156.
60. Stornetta R.L., Guyenet P.G., McCarty R.C. Autonomic bervous system control of heart rate during baroreceptor activation in conscious and anaesthetized rats. J. Auton. Nerv. Syst. 1987, 20:121-127.
61. Subbiah I.M., Lenihan D.J., Tsimberidou A.M. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 2011, 16(8):1120-1130.
62. Testai L., Calderone V., Salvadori M.C., Breschi C., Nieri P., Martinotti E. QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. J. Appl. Toxicol. 2004, 24:217-222.
63. Testai L., Breschi M.C., Martinotti E., Calderone V. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II. J. Appl. Toxicol. 2007, 27:270-275.
64. Tocchetti C.G., Ragone G., Coppola C., Rea D., Piscopo G., Scala S., De Lorenzo C., Iaffaioli R.V., Arra C., Maurea N. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur. J. Heart Fail. 2012, 14(2):130-137.
65. Toyoshima S., Kanno A., Kitayama T., Sekiya K., Nakai K., Haruna M., et al. QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J. Pharm. Sci. 2005, 99:459-471.
66. Valentin J.P., Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J. Pharmacol. Toxicol. Methods 2008, 58:77-87.
67. Wallace A.G., Skinner N.S., Mitchell J.H. Hemodynamic determinants of the maximal rate of rise of left ventricular pressure. Am. J. Physiol. 1963, 205:30-36.
68. Yao X., Anderson D.L., Ross S.A., Lang D.G., Desai B.Z., Cooper D.C., Wheelan P., McIntyre M.S., Bergquist M.L., MacKenzie K.I., Becherer J.D., Hashim M.A. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. BJP 2008, 154(7):1446-1456.
69. Zausig Y.A., Stowe D.F., Zink W., Grube C., Martin E., Graf B.M. A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts. Anesth. Analg. 2006, 102:1646-1652.